

# Technical Design Report for a Carbon-11 Treatment Facility

*Liviu Penescu*


*MEDICIS-Promed Final Conference,  
29 April-4 May 2019 Erice, Italy*



# TDR contributors

Name	Affiliation
Thierry Stora	CERN
Fredrik Wenander	CERN
Johanna Pitters	CERN
Thomas Cocolios	KU Leuven
Simon Stegemann	KU Leuven
Ricardo Dos Santos Augusto	TRIUMF
Katia Parodi	LMU Munich
Elisa Fiorina	CNAO
Andrea Mairani	CNAO
Marco Pullia	CNAO
Claus Schmitzer	MedAustron
Liviu Penescu	Abstract Landscapes

# OVERVIEW



## Range uncertainties

### INDEPENDENT on dose calculation:

- Beam reproducibility
- Patient positioning and setup
- Measurements in water for commissioning

### DEPENDENT on dose calculation:

- CT calibration
- Tissue conversion
- Mean ionization energy estimation
- Range degradation for complex inhomogeneities

## Treatment verification via PET device



- Off-line (PET/CT)
- In-room (PET or PET/CT)
- In-beam (PET)

## Limitations of the PET imaging



- Noisy image from positron emitters produced by projectile fragmentation
- Long acquisition times (~2% of the primary beam undergo nuclear reactions, per cm)

# Imaging performance

<sup>11</sup>C



<sup>12</sup>C



FLUKA Simulation: Annihilation events at rest

Experimental data (A.U.)

## <sup>11</sup>C advantages:

- Higher relative concentration of signal in the Bragg peak vicinity
- A factor of two sharper peak
- Higher number of events (by one order of magnitude)

### FLUKA simulation:

- FLUKA PET tools
- Estimation of the annihilation events at rest

### EXPERIMENTAL data:

- openPET whole-body scanner (QST/NIRS)
- Beam irradiation in PMMA phantoms
- <sup>11</sup>C:  $5.4 \times 10^7$  particles (3 spills)
- <sup>12</sup>C:  $9 \times 10^7$  particles (5 spills)

## Lawrence Berkeley National Laboratory

$^{11}\text{C}$  via projectile fragmentation, 250 MeV/u,  $2 \cdot 10^7$  per pulse

- Primary beams:  $^{12}\text{C}$ , 350 MeV/u;  $^{18}\text{O}$ , 800 MeV/u
- Target: Be

11 MeV PET-cyclotron,  $\text{N}_2$  gas target

## HIMAC/NIRS

$^{11}\text{C}$  via projectile fragmentation, 355 MeV/u,  $7.2 \cdot 10^6$  per pulse

- Primary beam:  $^{12}\text{C}$ , 430 MeV/u;  $^{16}\text{O}$ , 800 MeV/u
- Target: Be

## Centre de Recherche du Cyclotron

$^{11}\text{C}$  at 120MeV/u,  $1 \cdot 10^8$  ions/s  
30 MeV cyclotron; Targets: BN,  $\text{B}_2\text{O}_3$

## CERN ISOLDE

$^{11}\text{C}$  without post-acceleration, intensities  $\leq 7.7 \cdot 10^8$  ions/s  
1.4GeV protons; Targets: multiple types

## ISAC/TRIUMF

$^{11}\text{C}$  without post-acceleration, intensities  $\leq 10^7$  ions/s  
500 MeV protons; Target: NiO/Ni

## SPECIFICATIONS: the same as for $^{12}\text{C}$ treatment facilities

### **SPILLS:**

0.1 to 10 seconds

### **ENERGIES:**

$\text{C}^{6+}$ : 120 to 400 MeV/u

- *Energies corresponding to 3-37 cm penetration depth in human tissue*
- *~1 minute to deliver 2 Gray in 1 L tumor volume*

### **INTENSITIES:**

$\text{C}^{6+}$ :  $\leq 4 \cdot 10^8$  particles/spill

*(4 intensity steps for each beam species)*

### **BEAM SIZES:**


4 to 10mm

*(4 size steps)*

## The main CHALLENGES to solve for a $^{11}\text{C}$ facility

- Production of  $^{11}\text{C}$
- Accumulation of  $^{11}\text{C}$
- Stable and reproducible performance

# FACILITY LAYOUT: key components/stages





# Radioisotope production



**H<sup>+</sup>**

OPTIONS:

- 7 MeV (existing facilities)
- 18 MeV (IBA KIUBE)
- 250 MeV (VARIAN ProBeam)

**N<sub>2</sub>**

vs.

**BN**

- Gaseous
- PET type
- Batch operation
- Solid
- ISOL type
- cw operation

**neutral**

vs.

**1+**

- Gas mixing in the target (O<sub>2</sub> or N<sub>2</sub>)
- Chromatography gas separation (of <sup>11</sup>CO<sub>2</sub> or <sup>11</sup>CH<sub>4</sub>)
- <sup>11</sup>CO delivered to a ECR ion source
- Beam deceleration

- In-target production yields (FLUKA)
- Isotope release efficiencies

OPTIONS

- Feasible intensity of primary beam
- Target geometry
- Molecular sideband

- Starting contaminants...
- Trapping efficiency
- Transport efficiency
- Process duration
- Remaining contaminants

*The resulting numbers are given in the talk of Simon Stegemann*

# $^{11}\text{C}$ Production: summary for $\text{N}_2$ targets



Accelerator	LEBIT-Linac	CYCLONE <sup>®</sup> KIUBE	VARIAN ProBeam <sup>™</sup>
Particle	proton	proton	proton
Energy [MeV]	7	18	250
Intensity [ $\mu\text{A}$ ]	7	50	0.8
Pulse structure	dc/ x Hz-y ms	dc/ x Hz-y ms	dc/ x Hz-y ms
Beam cross section [ $\text{mm}^2$ ]	Gauss $8.24^2$	Gauss $8.24^2$	Gauss $8.24^2$
batch/extraction time [min]	30 + 4 + 1	30 + 4 + 1	30 + 4 + 1
Target size, geometry	$40 \text{ cm}^3$	$40 \text{ cm}^3$	$40 \text{ cm}^3$
[S · L] [cm]	1.8·11.26 · 5.7	1.8·11.26 · 5.7	1.8·11.26 · 5.7
Target material	$\text{N}_2/\text{O}_2$	$\text{N}_2/\text{O}_2$	$\text{N}_2/\text{O}_2$
In-target yield	0.7	262 (176)	0.35
EOB [GBq]			
Technique	CGS	CGS	CGS
Separation efficiency [%]	40	40	40
Molecular sideband	$\text{CO}_2$	$\text{CO}_2$	$\text{CO}_2$
Residual impurities	$^{12}\text{CO}_2$ , ( $\text{N}_2$ , $\text{O}_2$ )	$^x\text{CO}_2$ , ( $\text{N}_2$ , $\text{O}_2$ )	$^x\text{CO}_2$ , ( $\text{N}_2$ , $\text{O}_2$ )
Injection EBIS			
[molecules]	$5 \cdot 10^{11}$	$2 \cdot 10^{14}$ ( $1 \cdot 10^{14}$ )	$2 \cdot 10^{11}$

# $^{11}\text{C}$ Production: summary for BN targets




Accelerator	LEBIT-Linac		CYCLONE <sup>®</sup> KIUBE		VARIAN ProBeam <sup>™</sup>	
Particle	proton		proton		proton	
Energy[MeV]	7		18		250	
Intensity [ $\mu\text{A}$ ]	7		50		0.8	
Pulse structure	dc/ x Hz-y ms		dc/ x Hz-y ms		dc/ x Hz-y ms	
Beam cross section [ $\text{mm}^2$ ]	Gauss $8.24^2$		Gauss $8.24^2$		Gauss $8.24^2$	
batch/extraction time [min]/cw	cw		cw		cw	
Target size, geometry [S · L] [cm]	cyl. 7.1·34.2		cyl. 7.1·34.2		cyl. 7.1·34.2	
Target material	BN		BN		BN	
In-target yield EOB [GBq]	12		593		63.4	
Release efficiency [%]	5	5	5	5	5	5
Technique	ISOL	CGS	ISOL	CGS	ISOL	CGS
Separation efficiency [%]	5	40	5	40	5	40
Molecular sideband	CO	CO <sub>2</sub>	CO	CO <sub>2</sub>	CO	CO <sub>2</sub>
Residual impurities	$^{13}\text{N}^{14}\text{N}$	$^x\text{CO}_2$	$^{13}\text{N}^{14}\text{N}$	$^x\text{CO}_2$	$^{13}\text{N}^{14}\text{N}$	$^x\text{CO}_2$
Injection EBIS	$5 \cdot 10^{10}$	$4 \cdot 10^{11}$	$3 \cdot 10^{12}$	$2 \cdot 10^{13}$	$3 \cdot 10^{11}$	$2 \cdot 10^{12}$
	[molecules/s]	[molecules]	[molecules/s]	[molecules]	[molecules/s]	[molecules]

# Ionization / Charge breeding



## How we got to this conclusion:


Initial evaluation:



➤ Too optimistic efficiencies

$5 \cdot 10^9$  particles per pulse

In-depth investigations:





- EBIS performance is technically possible
- The limitation comes mostly from the trapping process


# Acceleration

- **SYNCHROTRON: for existing facilities**
- **LINAC: an attractive alternative**

**The pulse length:**  
a key parameter for the injection into the synchrotron



# Integration to existing facilities




# The MedAustron case: potential scenarios


LINAC production

Medical cyclotron

Radiopharma cyclotron



# MedAustron: potential timeline



- Additional RP measures possible to implement
- A new Environmental Impact Analysis (EIA) needed



## Network with following expertise

- Cryotrap
- High-capacity EBIS
- Deceleration / soft landing
- Commercial partners

## Tests at a partner facility